Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

rges, acquired in-process research and development relating to license agreements and acquisitions, stock-based compensation expense, foreign exchange gains or losses relating to translation of foreign denominated items and other non-recurring items. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations and Adjusted EBITDA also exclude litigation expenses related to defending intellectual property claims. Revenue, as adjusted, excludes non-recurring, non-operating revenue derived from license agreements and other license revenue, net of license fees due to licensors and excludes amounts accrued for costs incurred. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations, revenue, as adjusted, and Adjusted EBITDA do not have any standardized meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other issuers. Management uses these non-GAAP or adjusted operating measures to establish operational goals and believes that these measures may assist investors in evaluating the results of the business and analyzing the underlying trends in our business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. We have provided a reconciliation of these measures to GAAP in the attached tables.

    Conference Call Information
    ----------------------------
    A conference call to discuss these financial results will be held today,
Thursday March 5, 2009 at 7:00 AM PT (10:00 AM ET).

    Dial-in information:
    North America (toll-free): (800) 291-9234
    International: (617) 614-3923
    Enter passcode: 52474180

    A replay archive of the conference call will be available until March 12,
2009 by calling (888) 286-8010 (in North America) or (617) 801-6888
(International) and entering 
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Portage Biotech Inc. ("Portage" or "the Company") (OTC Market: ... that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. (PPL) ... Investigational New Drug (IND) application for the topical treatment ... a study in a rat model of dry eye ... and a more rapid onset of action than 0.1% ...
(Date:8/31/2015)... Calif. and SHANGHAI ... a privately-held biopharmaceutical company developing next-generation antibiotics, today ... 2 clinical study for its lead drug candidate ... to treat drug-resistant bacteria such as MRSA and ... and better tolerated therapeutic option than currently available ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare AB ... to acquire YouMedical Group BV ("YouMedical"), a Dutch OTC ... total annual sales of approximately EUR 16 million, with ... "Our ambition is to build a leading ... step toward that goal. YouMedical gives us a stronger ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Mass., Sept. 19 Boston Scientific,Corporation (NYSE: BSX ... Life,Sciences Conference, which is being held September 22 - ... Chief Executive Officer, will make a,30-minute presentation which will ... Thursday, September 25, beginning at approximately 9:00,a.m. ET., ...
... PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will announce ... before the market opens., The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Therapeutics, LLC, a Michigan-based company, announced that it ... a license agreement for novel gene-therapy approaches for ... of Medicine. Zhuo-Hua Pan, Ph.D., professor ... of Medicine, along with colleagues at Salus University ...
... and for worse, human health depends on a cell,s motility ... every human body, millions of cells are crawling around doing ... are cancerous, watch out. "This is not some horrible ... their daily duties," said Florida State University cell biologist Tom ...
... A comprehensive database developed by King,s College London researchers ... medicines has been released to market this month, allowing ... tomorrow,s new drugs. Provided under licence to Tim ... database is the most comprehensive of its kind. Featuring ...
Cached Biology News:Wayne State announces license agreement for breakthrough approaches to vision restoration 2Cells are crawling all over our bodies, but how? 2Cells are crawling all over our bodies, but how? 321st century database of traditional Chinese medicine released 2
... Panomer 9 oligodeoxynucleotides ... are labeled at the ... proprietary Alexa Fluor dyes ... for assessing microarray spot ...
... l-[U-14C]methionine, 1.85 MBq, 50 uCi. Aqueous ... > 1.85 GBq/mg atom carbon, > ... of Ala, Arg, Asp, Glu, Gly, ... Ser, Thr, Tyr and Val.1.85 MBq/ml, ...
Alkaline Phosphatase Stabilizer Solution, 1 L...
... Express Cloning Checker Kits provide two highly ... transformation without time-consuming plasmid preparation. By using ... all you need to do is to ... directly from the transformation plates into the ...
Biology Products: